ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2001

Adenosine A2A Receptor Stimulation Regulates Autophagy in Chondrocytes

Benjamin Friedman1, Carmen Corciulo2, Cristina Castro3 and Bruce N. Cronstein1, 1Rheumatology, New York University School of Medicine, New York, NY, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Medicine, NYU School of Medicine, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors, autophagy, chondrocytes and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Osteoarthritis (OA) is a debilitating condition characterized by chondrocyte dysfunction and loss of cartilage. Autophagy, a homeostatic process that occurs in times of cellular stress and starvation, is decreased in chondrocytes with aging and OA. The adenosine A2A receptor (A2AR) maintains chondrocyte homeostasis; A2AR knockout (KO) mice spontaneously develop OA. Moreover, intra-articular injection of liposomal preparations of adenosine or an A2AR-specific agonist (CGS12680 (CGS)) in rats with post-traumatic OA (PTOA) or mice with obesity-induced OA prevents development of PTOA and reverses obesity-induced OA. We sought to determine whether adenosine signaling maintains chondrocyte homeostasis, in part, by regulating autophagic flux in chondrocytes.

Methods:

Autophagy proteins Beclin-1, p62/SQSTM1, and LC3 were analyzed by western blotting and IF in TC28⍺2 human chondrocytes ±1µM CGS for various times in normal culture and starvation (FBS 10% vs 1%). Chondrocytes were pretreated with autophagy inhibitors hydroxychloroquine (prevents autophagosome destruction by lysosomes, 25µM, HCQ) and/or 3-methyladenine (blocks autophagy initiation, 3MA, 5mM). Knee joint sections from obese mice treated with adenosine or CGS were analyzed by fluorescent IHC. Autophagy gene expression was determined in differential display analyses comparing wildtype (WT) vs A2AR KO mice and rats with established PTOA treated with intra-articular injections of liposomal CGS or liposomes alone.

Results:

Consistent with enhanced autophagy, CGS reduced p62 levels in starved chondrocytes by western blot (4.1 ± 0.7 vs 5.7 ± 0.8 p62/actin, p<0.02). More cells stained diffusely positive for p62 without punctae (less autophagy) in the control vs CGS (67 ± 6% vs. 19 ± 3%, p<0.0002). With HCQ added, punctate p62 was more marked and brighter on CGS treatment (78 ± 5% vs 13 ± 4%, p<0.0001). Chondrocyte pre-treatment with 3-MA (±HCQ) followed by starvation ±CGS for 1h demonstrated almost complete absence of either p62 or Beclin-1. When studied in vivo in OA mouse knees, Beclin-1 was not visible in chondrocytes in normal and obese (OA) mouse controls whereas it was present in all of the chondrocytes in obese mice treated with either CGS or adenosine (p<0.0001). Differential expression analysis of WT vs A2AR KO murine chondrocytes demonstrated significant changes in numerous autophagy genes; e.g. p62 was elevated in WT mice. Similarly, there were significant changes in autophagy gene expression in PTOA rats given liposomal-CGS vs liposome. Of note the autophagy Atg8-family member Gabarapl1 that integrates into autophagosomes was increased with CGS-liposome injections (FC +1.75, adj p=0.0049).

Conclusion:

These results demonstrate, both in vitro and in vivo, that A2AR stimulation promotes autophagy, evidenced by decreased p62, increased Beclin-1 and reversal of these effects with autophagy inhibitors. Although the precise mechanism is not known, it is possible that A2AR signaling increases Beclin-1 activity, thereby increasing downstream autophagic flux. This increase in autophagy may contribute to maintaining chondrocyte homeostasis and reversing OA.


Disclosure: B. Friedman, None; C. Corciulo, Regenosine, 1,Intellectual property, 9; C. Castro, None; B. N. Cronstein, Cantic Biopharma, Regenosine, 1,NIH Arthitis foundation, Astrazeneca, 2,Horizon Pharmaceuticals, Regenosine, 5,Patent issued and pending, 9.

To cite this abstract in AMA style:

Friedman B, Corciulo C, Castro C, Cronstein BN. Adenosine A2A Receptor Stimulation Regulates Autophagy in Chondrocytes [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/adenosine-a2a-receptor-stimulation-regulates-autophagy-in-chondrocytes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptor-stimulation-regulates-autophagy-in-chondrocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology